Research Topics
Species | U FuhrSummaryAffiliation: University of Cologne Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome p450 enzymes in healthy volunteersOxana Doroshyenko
Institut fur Pharmakologie, Klinische Pharmakologie, Universitat zu Koln, Gleueler Straße 24, 50931 Koln, Germany
Drug Metab Dispos 41:987-93. 2013..Silexan and the phenotyping drugs were well tolerated. Repeated silexan (160 mg/day) administration has no clinically relevant inhibitory or inducing effects on the CYP1A2, 2C9, 2C19, 2D6, and 3A4 enzymes in vivo...
Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approachU Fuhr
Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Cologne, Germany
Clin Pharmacol Ther 81:270-83. 2007....- Improvement in the handling of drug-drug interactionsUwe Fuhr
Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Koln, Germany
Eur J Clin Pharmacol 64:167-71. 2008..Therefore, the incorporation of DDIs in a more general procedure for personalisation of drug therapy is desirable... - Individual variation in factors affecting the steps between dose application and effects of antineoplastic agentsU Fuhr
Department of Pharmacology, University of Cologne, Germany
Int J Clin Pharmacol Ther 43:573-4. 2005 - Toxicokinetics of acrylamide in humans after ingestion of a defined dose in a test meal to improve risk assessment for acrylamide carcinogenicityUwe Fuhr
Department of Pharmacology, University Hospital, University of Cologne, Gleueler Strasse 24, 50931 Cologne, Germany
Cancer Epidemiol Biomarkers Prev 15:266-71. 2006..This should be considered for quantitative cancer risk assessment... - The effect of silymarin on oral nifedipine pharmacokineticsUwe Fuhr
Department of Pharmacology, University Hospital, University of Cologne, Cologne, Germany
Planta Med 73:1429-35. 2007..Silymarin thus is not a potent CYP3A4 inhibitor IN VIVO... - Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphanK Abduljalil
Department of Pharmacology, Clinical Pharmacology Unit, University Hospital, University of Cologne, Cologne, Germany
Clin Pharmacol Ther 88:643-51. 2010..Urinary pH was confirmed as a significant covariate for DM renal clearance. These results refine genotype-based predictions of pharmacokinetics for DM and presumably for other CYP2D6 substrates as well... - Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?D Tomalik-Scharte
Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Cologne, Germany
Clin Pharmacol Ther 86:147-53. 2009..Further studies to address the temporal variations in local CYP3A activity are needed to assess its role as a biomarker during CYP3A inhibition... - Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndromeJ J Vehreschild
Department I of Internal Medicine, University of Cologne, Cologne, Germany
Eur J Clin Pharmacol 68:987-95. 2012..To estimate the pharmacokinetic (PK) properties of posaconazole in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing chemotherapy in a clinical setting... - Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevanceU Fuhr
Institute for Pharmacology, Universitat zu Koln, Germany
Drug Saf 18:251-72. 1998..A place for grapefruit juice as a drug-sparing agent in treatment involving expensive medicine cannot be derived from the information currently available on grapefruit juice interactions... 
Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteersG Zadoyan
Department of Pharmacology Clinical Pharmacology Unit, University of Cologne, Gleueler Str 24, 50931, Cologne, Germany
Eur J Clin Pharmacol 68:553-60. 2012..We assessed the human in vivo metabolic drug interaction profile of Ginkgo biloba extract EGb 761® with respect to the activities of major cytochrome P450 (CYP) enzymes...- The clinical role of genetic polymorphisms in drug-metabolizing enzymesD Tomalik-Scharte
Department of Pharmacology, Clinical Pharmacology, University of Cologne, Koln, Germany
Pharmacogenomics J 8:4-15. 2008..However, more prospective studies with clinical endpoints are needed before the paradigm of 'personalized medicine' based on DME variants can be established... - Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotypingD Frank
Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Strasse 24, 50931, Koln, Germany
Eur J Clin Pharmacol 63:321-33. 2007..Appropriate metrics need to fulfill pre-defined validation criteria... - Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administrationS Schroder
Department of Pharmacology, Clinical Pharmacology, University of Cologne, Cologne, Germany
Int J Clin Pharmacol Ther 42:543-9. 2004..The present study was performed to assess the influence of intestinal site on absorption of the drug as the basis for the development of modified release preparations... - Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variantsD Rokitta
Department of Pharmacology, University of Cologne, Gleueler Str 24, 50931 Cologne, Germany
Curr Drug Metab 11:153-61. 2010..1, CYP2C9.2 and CYP2C9.3), CYP2C8 and/or CYP2C19. Particularly contradictory findings for the same reactions call for some standardization in the assessment of enzyme kinetics... - Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteersD Tomalik-Scharte
Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Str 24, 50931 Koln, Germany
Drug Metab Dispos 33:1859-66. 2005..93-1.00, 0.84-0.96, and 0.97-1.07, respectively). All study drugs were well tolerated. In conclusion, propiverine has a minor potential to cause drug-drug interactions... - Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patientsC Wyen
Department of Internal Medicine, Hospital of the University of Cologne, Koln, Germany
Clin Pharmacol Ther 84:75-82. 2008..In conclusion, CYP3A, CYP2D6, and P-glycoprotein are profoundly inhibited in patients receiving ritonavir boosted lopinavir. The covariates investigated are not useful for a priori dose selection... - Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancerM Hunz
Department of Pharmacology, Clinical Pharmacology, University of Cologne, Cologne, Germany
Clin Pharmacol Ther 81:659-68. 2007..Epirubicin doses were significantly correlated to tumor exposure irrespective of body surface area. There is no specific barrier for epirubicin to reach primary breast cancer tumors... - Liver cytochrome P450 CYP1A2 is markedly inhibited by systemic but not by bath PUVA in dermatological patientsI Tantcheva-Poor
Institute for Pharmacology, Clinical Pharmacology, 50931 Koln, Germany
Br J Dermatol 144:1127-32. 2001..Methoxsalen (8-MOP) may cause important pharmacokinetic drug interactions as it has been shown to inhibit and/or induce several drug-metabolizing enzymes in vitro, in animal models and in humans... - Pharmacogenetics-based therapeutic recommendations--ready for clinical practice?Julia Kirchheiner
Department of Pharmacology, University of Cologne, Gleueler Strasse 24, 50931, Koln, Germany
Nat Rev Drug Discov 4:639-47. 2005..Here, we argue for the development of concise guidelines for implementation of PGx analyses in drug development and therapy... - Influence of posture on pharmacokineticsChristian Queckenberg
Department of Pharmacology, Clinical Pharmacology, University Hospital, University of Cologne, Cologne, Germany
Eur J Clin Pharmacol 65:109-19. 2009..These characteristics may interact with key factors determining the pharmacokinetics of drugs (dissolution, absorption, distribution, metabolism, excretion)... - Absorption, pharmacokinetics, and safety of triclosan after dermal administrationChristian Queckenberg
Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Gleueler Str 24, D 50931 Cologne, Germany
Antimicrob Agents Chemother 54:570-2. 2010..Triclosan can be considered safe for use in hydrophobic creams... - Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinideDorota Tomalik-Scharte
Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Strasse 24, 50931 Koln, Germany
Drug Metab Dispos 39:927-32. 2011..In conclusion, CYP2C8*3 does not seem to play an important role in the pharmacokinetics and pharmacodynamics of repaglinide given in a therapeutic dose... - ["Clinically significant" new drug interactions]U Fuhr
Klinische Pharmakologie, Universitat zu Koln
Med Klin (Munich) 94:120-4. 1999..Several actual examples on interactions with selective serotonin re-uptake inhibitors, HMG-CoA reductase inhibitors, mibefradil, sildenafil, protease inhibitors and with grapefruit juice are discussed... - Rate-limiting biotransformation of triamterene is mediated by CYP1A2U Fuhr
Institute for Pharmacology, Clinical Pharmacology, University of Cologne, Germany
Int J Clin Pharmacol Ther 43:327-34. 2005..To identify the cytochrome P450 enzyme(s) catalyzing hydroxylation of triamterene (the rate-limiting step in the formation of the sulfate ester (STA)), in vitro incubation studies were performed with human liver microsomes... - Biotransformation of methylxanthines in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Allocation of metabolic pathways to isoforms and inhibitory effects of quinolonesU Fuhr
Department of Clinical Pharmacology, University Hospital, Frankfurt am Main, Germany
Toxicology 82:169-89. 1993..Theophylline was mainly metabolized via 8-hydroxylation. All cell lines tested were able to carry out this reaction, with highest activities in cell lines expressing rat or human P450IA2, or rat P450IA1... - Population pharmacokinetics of cyclophosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapyS Wilde
, , Klinische Pharmakologie, Germany
Int J Clin Pharmacol Ther 40:586-8. 2002 - [Clinically significant" new drug interactions]U Fuhr
Klinische Pharmakologie, Universitat zu Koln
Med Klin (Munich) 95:18-22. 2000..Several actual examples on interactions with selective serotonin re-uptake inhibitors, HMG-CoA reductase inhibitors, mibefradil, sildenafil, protease inhibitors and with grapefruit juice are discussed... - Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantationV Kohl
Department of Pharmacology, University of Cologne, Cologne, Germany
Antimicrob Agents Chemother 54:207-12. 2010..Corresponding adjustments of the starting dose according to the presence of diarrhea and according to age appear to be justified before TDM results are available... - Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and GenotropinUwe Fuhr
Clinical Pharmacology Unit, Department of Pharmacology, Hospital of the University of Cologne, Cologne, Germany
Eur J Endocrinol 162:1051-8. 2010..Two strengths of a novel ready-to-use liquid preparation of the recombinant human GH (rhGH) Omnitrope were developed to increase the convenience for the patients... - In vivo role of cytochrome P450 2E1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humansOxana Doroshyenko
Department of Pharmacology, University of Cologne, Cologne, Germany
Cancer Epidemiol Biomarkers Prev 18:433-43. 2009..No obvious genetic risks or protective factors in xenobiotic-metabolizing enzymes could be determined for exposed subjects... - Cytochrome P450 2C9 phenotyping using low-dose tolbutamideAlexander Jetter
Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Strasse 24, 50931 Cologne, Germany
Eur J Clin Pharmacol 60:165-71. 2004..However, therapeutically active doses of 500 mg bear the risk of hypoglycaemia, and a tolbutamide-derived parameter based on a single plasma or urine concentration reflecting CYP2C9 activity accurately is lacking... - Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humansU Fuhr
Institute for Pharmacology, Clinical Pharmacology, University of Cologne, Germany
Clin Pharmacokinet 38:493-504. 2000..The toxicological consequences of enzyme induction in humans are rare, and appear to be mainly limited to hepatoxicity in ethanol-type induction... - Dermal absorption of permethrin following topical administrationD Tomalik-Scharte
Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Cologne, Germany
Eur J Clin Pharmacol 61:399-404. 2005..These data provide the pharmacokinetic basis for the clinical safety of topical permethrin... - Clinical pharmacokinetics of trospium chlorideOxana Doroshyenko
Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Cologne, Germany
Clin Pharmacokinet 44:701-20. 2005..The pharmacokinetics of the drug are compatible with twice-daily administration. A once-daily schedule may also be appropriate, but this regimen needs formal clinical evaluation... - How may anticancer chemotherapy with fluorouracil be individualised?Su arpa Ploylearmsaeng
Department of Pharmacology, Clinical Pharmacology, University Hospital of Cologne, Cologne, Germany
Clin Pharmacokinet 45:567-92. 2006.... - Pharmacogenetics of oral anticoagulants: a basis for dose individualizationSimone Stehle
Department of Pharmacology, University of Cologne, Cologne, Germany
Clin Pharmacokinet 47:565-94. 2008.... - Assessment of CYP1A2 activity in clinical practice: why, how, and when?Mirko S Faber
Department of Pharmacology, Clinical Pharmacology, University of Cologne, Koln, Germany
Basic Clin Pharmacol Toxicol 97:125-34. 2005..CYP1A2 phenotyping is applied frequently in epidemiologic and drug-drug interaction studies, but its clinical use and usefulness remains to be established... - Modelling ocular pharmacokinetics of fluorescein administered as lyophilisate or conventional eye dropsKhaled Abduljalil
Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Gleueler Str 24, D 50931, Koln, Germany
Eur J Clin Pharmacol 64:521-9. 2008.... - CYP1A1 alleles in women with focal nodular hyperplasia of the liver (FNH)A Lazar
Department of Pharmacology, University Hospital, University of Cologne, Clinical Pharmacology, Germany
Int J Clin Pharmacol Ther 42:78-82. 2004..In the study at hand, we aimed to evaluate a possible association between CYP1A1*1, *2A, *2B, and *4 alleles and FNH... - Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposureAlexander Jetter
Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Strasse 24, 50931 Koln, Germany
Eur J Clin Pharmacol 60:17-21. 2004..We tested whether these standardization measures were still needed when a more sensitive quantification technique was used... - An amperometric biosensor with human CYP3A4 as a novel drug screening toolShiba Joseph
Institute for Pharmacology, Clinical Pharmacology, , , Germany
Biochem Pharmacol 65:1817-26. 2003..Thus, important requirements for the application of human CYP biosensors in order to identify drugs or drug candidates as substrates or inhibitors to the attached enzyme are fulfilled... - Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2Andreas Labedzki
Institute for Pharmacology, Clinical Pharmacology, , Gleueler Strasse 24, , Germany
Biochem Pharmacol 63:2159-67. 2002..Our results suggest that an interspecies comparison is required for the metabolism of individual xenobiotics interacting with CYP1A2 prior to the use of mice models to predict its toxicity and/or pharmacological activity in man... - The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitroEugen Muschler
Department of Pharmacology, University of Cologne, Cologne, Germany
Basic Clin Pharmacol Toxicol 105:374-9. 2009..The evidence for substrate-specific inhibitory effects of pioglitazone on CYP2C-mediated metabolism needs to be tested in further studies... - Modeling the autoinhibition of clarithromycin metabolism during repeated oral administrationKhaled Abduljalil
Department of Pharmacology, Clinical Pharmacology, University Hospital, University of Cologne, Cologne, Germany
Antimicrob Agents Chemother 53:2892-901. 2009..6-fold higher level of clarithromycin exposure than the 500-mg b.i.d. dose. This evaluation provides a rationale for safer and more effective therapy with clarithromycin... - Mesalazine pharmacokinetics and NAT2 phenotypeHendrik Lück
Department of Pharmacology, University Hospital, University of Cologne, Cologne, Germany
Eur J Clin Pharmacol 65:47-54. 2009..Mesalazine undergoes extensive metabolism by N-acetylation. While there is some evidence for an involvement of N-acetyltransferase (NAT) type 1, a potential role of NAT type 2 (NAT2) in vivo has not been tested... - Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicityStefan Wilde
Department of Pharmacology, University Hospital, University of Cologne, Cologne, Germany
Clin Pharmacokinet 46:319-33. 2007..The present study was conducted to address the role of pharmacokinetics in individual toxicity... - Time response of cytochrome P450 1A2 activity on cessation of heavy smokingMirko S Faber
Department of Pharmacology, Clinical Pharmacology, University of Cologne, , Germany
Clin Pharmacol Ther 76:178-84. 2004..As a rule of thumb, a stepwise daily dose reduction of approximately 10% until the fourth day after smoking cessation is proposed, which should be accompanied by therapeutic drug monitoring... - What is the true risk of a pharmacokinetic drug-drug interaction?Uwe Fuhr
Eur J Clin Pharmacol 63:897-9. 2007 - Effects of grapefruit juice and smoking on verapamil concentrations in steady stateUwe Fuhr
Institute for Pharmacology, Clinical Pharmacology, University of Koln, Germany
Eur J Clin Pharmacol 58:45-53. 2002..Both enzymes contribute to verapamil biotransformation. This study was performed to quantitatively assess the effect of these factors on verapamil pharmacokinetics in steady state... - Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?Martina Kinzig-Schippers
Institute for Biomedical and Pharmaceutical Research, Paul Ehrlich Strasse 19, 90562 Nürnberg Heroldsberg, Germany
Antimicrob Agents Chemother 49:1733-8. 2005..Prospective clinical trials are required to assess the merits of this approach... - Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activityTobias Klaassen
Department of Pharmacology, Clinical Pharmacology, Hospital of the University of Cologne, Gleueler Str 24, 50931, Koln, Germany
Eur J Clin Pharmacol 64:387-98. 2008..We also assessed whether urinary excretion of N-desmethylmephenytoin (nirvanol) might be a useful CYP2B6 metric in in vivo studies... - Do data presented at an American Society for Clinical Pharmacology and Therapeutics meeting make it to full publication?Markus Riessland
Clin Pharmacol Ther 75:123-4. 2004 - The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteersAlexander Jetter
Clin Pharmacol Ther 78:441-3. 2005 - Cytochrome P450 enzymes contributing to demethylation of maprotiline in manLars Brachtendorf
Institute for Pharmacology, Clinical Pharmacology, , Germany
Pharmacol Toxicol 90:144-9. 2002..Based on the parameters obtained, for plasma concentrations of 1 microM 83% (mean) of desmethylmaprotiline formation in vivo is expected to be mediated by CYP2D6 while 17% only may be attributed to CYPIA2 activity... - Effects of grapefruit juice on the pharmacokinetics of sildenafilAlexander Jetter
Institute for Pharmacology, Clinical Pharmacology, University of Koln, Germany
Clin Pharmacol Ther 71:21-9. 2002..In this study we investigated the influence of grapefruit juice, containing inhibitors of intestinal CYP3A4, on the pharmacokinetics of sildenafil and N -desmethylsildenafil... - Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotypeJulia Kirchheiner
Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Germany
Clin Pharmacol Ther 80:657-67. 2006..The purpose of this was to clarify the role of this polymorphism with regard to the pharmacokinetics and clinical effects of rosiglitazone...